Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)

Completed · Phase 3 · Has a placebo group

Conditions studied: Bladder Cancer

In brief

The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.

Key facts

Study ID
NCT00461591
Run by
Spectrum Pharmaceuticals, Inc
People needed
802
Starts
2007-04-01
Expected to finish
2012-01-01
Last updated by the study team
2021-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.